When a “+” Sign Isn’t Just a Plus

On July 6, 2026, the Central Drugs Standard Control Organisation (CDSCO) — India’s apex drug regulator — issued a public notice inviting stakeholder comments on a sensitive issue: pharmaceutical companies marketing multiple drug formulations under the same established brand name, distinguished only by minor suffixes or extensions.

The notice traces back to the 67th Drugs Consultative Committee (DCC) meeting held on November 17, 2025, where regulators were flagged a specific pattern: a pharma company selling different drug formulations — with different active pharmaceutical ingredients (APIs) — under one recognizable brand name, tweaked only slightly. The DCC’s concern was direct: this practice risks misleading consumers and creating confusion about a medicine’s actual therapeutic use.

At the time the notice went out, it read like a forward-looking regulatory exercise — theoretical, procedural, the kind of thing that moves slowly through committees. Five days later, it stopped being theoretical.

On July 12, 2026, the Maharashtra FDA announced a major enforcement action against Cadila Pharmaceuticals Ltd. that reads almost like a textbook illustration of exactly what the CDSCO notice was warning about.

The products in question: Aciloc 150, Aciloc 300, and their “Plus” counterparts, Aciloc 150+ and Aciloc 300+. Cadila had long held approval to sell Aciloc 150 and Aciloc 300 with Ranitidine as the active ingredient. But at some point, the company introduced Aciloc 150+ and Aciloc 300+ — and swapped Ranitidine out entirely for Famotidine, a completely different API used to treat similar acid-related conditions but chemically distinct.

The problem wasn’t the reformulation itself. It was the branding. Despite replacing the active ingredient, the company kept nearly identical packaging and label artwork across both versions. The only visual cue separating a Ranitidine-based product from a Famotidine-based one was a small “+” symbol tacked onto the name.

A routine inspection in Amravati brought the issue to light, and the investigation found that both the older Ranitidine-based Aciloc products and the newer Famotidine-based Aciloc Plus products were being sold simultaneously in the market. That overlap is precisely the scenario regulators worry about: a doctor, pharmacist, or patient reaching for a familiar name and unknowingly ending up with a different drug altogether.

The Maharashtra FDA responded firmly — it ordered a complete recall of all four product variants from the market and barred further sale of the Plus versions, while seizing stock worth roughly Rs 2.45 crore from carrying-and-forwarding warehouses across the state.

Regulatory notices often feel abstract until a real case gives them shape. Here, the gap was just days. CDSCO’s July 6 notice described, almost eerily, the exact mechanism at play in Amravati: a trusted brand name retained across formulations with genuinely different APIs, creating exactly the kind of confusion the DCC had flagged back in November.

Regulatory guidelines already state that when a branded medicine’s active ingredient or composition changes, the revised product should not be marketed under the same or a deceptively similar brand name. The Cadila case suggests that principle isn’t yet consistently enforced — or that the incentive to ride an established brand’s recognition is strong enough that companies test the boundary anyway.